A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
Trial Parameters
Brief Summary
This study aims to provide a basis for further clinical development of YKST02. YKST02 is a study medicine that targets multiple myeloma and activates the human body to fight against this disease.
Eligibility Criteria
Inclusion Criteria: 1. Participants or their legally acceptable representative must sign an ICF indicating that the participants understand the purpose of, and procedures required for the study and are willing to participate in the study. 2. Diagnosis of multiple myeloma according to the IMWG criteria. 3. Receipt of at least two prior classes of drugs either in separate regimens or as combinations. The three classes are defined as: An immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 drug. 4. Measurable disease at screening, as defined by at least 1 of the following: 1. Serum M-protein ≥0.5 g/dL; 2. Urinary M-protein excretion ≥200 mg/24 hours; 3. Abnormal serum free light chain (FLC) ratio ( \<0.26 or \>1.65) and serum immunoglobulin FLC≥10 mg/dL. 5. Eastern Cooperative Oncology Group Performance Status (ECOG) of 0-1. 6. An estimated survival time of more than 12 weeks. 7. Recovery to Grade 0-1 (Graded by National Cancer Institute Common Toxicity Criteria for Adverse Eve